CompanyGraph
Guardant Health Inc.
GH · United States
Tests a patient's blood for cancer mutations by matching DNA fragments against a database built from over one million prior patients.
Guardant Health takes a blood sample from a cancer patient, sequences over 730 genes worth of cell-free DNA fragments shed by tumor cells, and then checks each detected variant against a library of mutation patterns accumulated from more than one million prior patient samples to determine whether a low-frequency signal is a real cancer mutation or instrument noise. That library is what makes the test clinically useful — at allele frequencies as low as 0.1%, sequencing hardware alone cannot tell the two apart, so without the reference database the results cannot guide treatment decisions. Every new sample processed either confirms a known pattern or adds a new resistance signature to the library, so the database grows more powerful with volume, and because FDA companion diagnostic approvals for specific drugs are tied to the Guardant360 CDx assay by name, oncology practices using those drug indications cannot swap in a competitor's test without losing regulatory compliance — which keeps the sample flow coming and the database growing. The structural vulnerability is that if a regulatory change froze or quarantined the database, novel mutations emerging in patients would have no reference to be checked against, and the artifact-discrimination that the entire test's credibility rests on would gradually erode regardless of how well the sequencing machines perform.
How does this company make money?
The main source of revenue is per-test billing: each time a Guardant360 test is ordered, the company bills the patient's insurance or Medicare, typically collecting between $3,000 and $5,000 depending on which panel was run. The company also earns money from pharmaceutical companies through partnership contracts — those deals provide upfront payments and milestone fees in exchange for companion diagnostic development and support for clinical trials.
What makes this company hard to replace?
Oncology practices that use Guardant360 CDx as an FDA-approved companion diagnostic for specific drug approvals cannot replace it with a different test without losing regulatory compliance for those therapies — the approval is tied to this specific assay. Switching also requires IT teams to revalidate laboratory information system integrations that handle results reporting, which takes time and money. And because individual patients build up a baseline genomic profile through repeated Guardant360 tests, those historical records cannot be transferred to a competing platform, making continuity of care another reason to stay.
What limits this company?
Tumor cells shed DNA into the blood at rates that vary by cancer type, stage, and individual patient, and no improvement in sequencing machines can change that biology. So the real ceiling on what the test can reliably detect is not how fast the sequencer runs — it is whether the mutation database is large and current enough to recognize a new low-frequency variant when it appears for the first time.
What does this company depend on?
The company cannot run without Illumina next-generation sequencing platforms, which perform the actual DNA analysis. It also depends on specialized blood collection tubes that keep cell-free DNA intact during transport to the lab, FDA breakthrough device designation and the laboratory developed test regulatory pathway to stay legally authorized, and Clinical Laboratory Improvement Amendments certification to operate as a high-complexity testing lab.
Who depends on this company?
Oncologists prescribing targeted cancer therapies rely on Guardant360 to monitor whether a patient's tumor is changing and whether a treatment should be adjusted — without it, that real-time visibility disappears. Pharmaceutical companies running precision oncology trials use the test to identify which patients qualify for a given drug; losing it would disrupt patient selection for those trials. Cancer patients being evaluated for immunotherapy depend on the company's TissueNext platform for PD-L1 expression analysis, which informs whether that treatment is appropriate for them.
How does this company scale?
Once the bioinformatics algorithms are built and the database is populated, running an additional sample through them costs almost nothing extra — the analysis layer scales cheaply. What does not scale cheaply is the laboratory work itself: isolating and quality-checking circulating tumor DNA requires trained technicians, that expertise cannot be automated away, and the number of technicians needed grows in direct proportion to the number of samples processed.
What external forces can significantly affect this company?
Medicare coverage decisions for liquid biopsy testing directly control how many doctors order the test and how much the company gets paid per result. If the FDA changes its rules for laboratory developed tests, the company could face expensive new clinical validation requirements before it could keep selling. Consolidation among oncology practices shifts negotiating power and can change which tests a large practice chooses to order.
Where is this company structurally vulnerable?
If a regulatory change — an FDA rule shift on laboratory developed tests, a CMS decision to stop reimbursing the test, or a data-security breach requiring the database to be locked down — froze the mutation reference library at its current state, the damage would build gradually but irreversibly. New resistance mutations would keep appearing in patients, the static database would no longer recognize them, and the test's ability to make reliable calls at sub-1% detection levels would quietly erode, taking the companion diagnostic designations with it.